Literature DB >> 4068796

Health status, sociodemographic factors, and the use of prescribed psychotropic drugs.

K B Wells, C Kamberg, R Brook, P Camp, W Rogers.   

Abstract

The relations among sociodemographic factors, health status, and use of prescribed sleeping pills and tranquilizers are examined. The data are from the Rand Health Insurance Experiment, which has a random sample of the nonaged, noninstitutionalized, civilian population in six U.S. sites. Information on sociodemographic factors, health status, and the use of prescribed psychotropic drugs during the previous 3 months was obtained from self-report questionnaires collected at enrollment. Mental and physical health status have large independent and significant effects on the probability of use of both prescribed tranquilizers (P less than 0.0001) and sleeping pills (P less than 0.0001), whether or not we remove the effects of sociodemographic factors. For the probability of tranquilizer use, there is no significant interaction between gender and mental health or between mental health and physical health. Age and gender have large and significant effects on the use of prescribed psychotropic drugs even after controlling for differences in health status and other demographic factors. The effects of site and socioeconomic status are modest compared with the effects of health, age, and gender.

Mesh:

Substances:

Year:  1985        PMID: 4068796     DOI: 10.1097/00005650-198511000-00008

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  15 in total

1.  Risk factors associated with problem use of prescription drugs.

Authors:  Linda Simoni-Wastila; Gail Strickler
Journal:  Am J Public Health       Date:  2004-02       Impact factor: 9.308

2.  Impact of consumer fees on drug utilisation.

Authors:  D G Smith; D M Kirking
Journal:  Pharmacoeconomics       Date:  1992-10       Impact factor: 4.981

3.  An international survey of the educational activities of schools of pharmacy on psychoactive drugs.

Authors:  J Falkowski; A H Ghodse; R Dickinson; I Khan
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

4.  Benzodiazepine prescriptions and therapist non-compliance.

Authors:  B Geiselmann; M Linden; N Sachs-Ericsson
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

5.  Development of long term use of psychotropic drugs by general practice patients.

Authors:  A Mant; P Duncan-Jones; D Saltman; C Bridges-Webb; L Kehoe; G Lansbury; A H Chancellor
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-23

6.  Use of tranquilizers and sleeping pills among cancer patients is associated with a poorer quality of life.

Authors:  O Paltiel; A Marzec-Boguslawska; V Soskolne; S Massalha; M Avitzour; R Pfeffer; N Cherny; T Peretz
Journal:  Qual Life Res       Date:  2004-12       Impact factor: 4.147

7.  Medical and psychosocial factors predictive of psychotropic drug use in elderly patients.

Authors:  L D Ried; D B Christensen; A Stergachis
Journal:  Am J Public Health       Date:  1990-11       Impact factor: 9.308

8.  Racial differences in the use of antidepressants and counseling for depression among homeless women.

Authors:  Betsy L Sleath; Elizabeth Jackson; Kathleen C Thomas; James Galloway; Lisa Dumain; Joshua Thorpe; Angela Rollins; Joseph Morrissey
Journal:  Community Ment Health J       Date:  2006-02

9.  Increased risk of ischaemic heart disease mortality in elderly men using anxiolytics-hypnotics and analgesics. Results of the 10-year follow-up of the prospective population study "Men born in 1914", Malmo, Sweden.

Authors:  J Merlo; B Hedblad; M Ogren; J Ranstam; P O Ostergren; A Ekedahl; B S Hanson; S O Isacsson; H Liedholm; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

10.  Psychoactive drug use in a general population sample, Sweden: correlates with perceived health, psychiatric diagnoses, and mortality in an automated record-linkage study.

Authors:  C Allgulander
Journal:  Am J Public Health       Date:  1989-08       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.